Breast Augmentation in UE
Breast Augmentation plastic surgery in UE section, includes general infrmation about Breast Augmentation Procedure, Breast Augmentation UE Local News, Breast Augmentation UE Surgeon Locator and other breast augmentation related materal.
UE Breast Augmentation - The Plastic Surgery Procedure
The plastic surgery operation is usually done when the breast reaches its final size after puberty (ages 17-18). Except for cases when there is congenital breast hypoplasia or breast asymmetry in which it can be done earlier (local regulations in UE may be applicable).
UE breast augmentation - the implants
There are three possible areas for the insertion of an implant for augmentation. The lower fold of the breast is the most common site. It allows full excess and lives a hidden scar. The second site is through the areola. This incision gives the best esthetic results but it is also the only one that goes through the breast tissue therefore the risk of infection and sensation loss is higher. The third one is through the armpits. Some plasit surgeons prefer it because the scar is almost invisible (except for those women who like to wear open close with no sleeves(. The disadvantage of this incision is a slight asymmetry of the breast. The decision usually made individually with each woman and the plastic surgeon (consult local UE surgeons).
The augmentation implant can be inserted above or below the chest muscles. The below position considered to be more preferable by most UE surgeons. There is less chance of feeling the implant, less chance of developing irregular folds or bumps on the surface of the breast and the implant is less likely to drop. This kind of plastic surgery technique is suitable for women with relatively little extra skin and less fallen breasts.
Most of the implants are made of silicon, and since the FDA determined that they safe for use they are being widely used by most plastic surgeons in UE.
[breast augmentation UE top]
UE breast augmentation - shape and size
The augmentation implants come in two shapes: round and pear shape also called "anatomic implants" because their shape resembles the natural contour of the breast. They are more expensive and require larger excision during the breast augmentation plastic surgery procedure.
The size of an implant usually depends on the woman size and proportions, the average size is 300cc. It is believed that smaller implants have lower complications.
[breast augmentation UE top]
UE breast augmentation - after the plastic surgery
After the augmentation plastic surgery you'll be wearing a sports bra or a bandage. You'll continue wearing them at all times day and night for about a month. You'll be able to take a shower 24 hours after the plastic surgery. The most optimal results usually seen 3 month after the surgery. Several things can complicate this plastic surgery procedure; those are rare complications, which you should be aware off. Bleeding around the area of the implant, infection, disturbances of sensation and touch around the nipples, silicon leak, rejection off an implant and some degree of irregularity on the surface of an implant.
Other Breast Augmentation Procedures
All Breast Plastic Surgery Procedures
UE Breast augmentation Plastic Surgery (current)
UE Breast Lift Plastic Surgery
UE Breast Implants Plastic Surgery
UE Implant Removal Plastic Surgery
UE Armpit Incision Plastic Surgery
More UE info...
United Arab Emirates Cities
Abu Dhabi - The capital of the UAE
Ajman - The smallest emirate, One of The Budget destinations.
Al Ain - Inland and close to the Omani bordertown of Buraimi, Al Ain comprises a triangle between the proper cities of Abu Dhabi and Dubai.
Dubai - The most common entry point for travelers, it is the transport and commerce center of the UAE.
Sharjah - A more budget destination, dusty and chaotic in places but with some charms.
United Arab Emirates Regions The seven emirates (imarat, singular - imarah) that make up the UAE are:
Abu Dhabi (Abu Zaby)
'Ajman
Fujairah (Al Fujayrah)
Sharjah (Ash Shariqah)
Dubai (Dubayy)
Ra's al Khaymah
Umm al Quwain The largest and wealthiest of these is Abu Dhabi, while probably the most well known is Dubai.
Breast AugmentationLatest Forum Posts...
- The British Association of Aesthetic Plastic Surgeons,The not-for-profit organisation established for the advancement of education and practice of Aesthetic Plastic Surgery for public benefit, denounced a website offering free breast augmentations as ‘degrading’ and warned British women that the process was entirely inappropriate for what should be a life-changing decision.
The BAAPS have learned that UK women are being lured into joining the ‘myfreeimplants.com’ site, where they post photos of themselves and a personal profile, meant to entice men to donate money to pay for their breast augmentation surgery.
Plastic Surgery News...
- During the annual American Association for the Advancement of Science meeting on Thursday in Boston, AAAS President David Baltimore said scientists are no closer to developing an HIV vaccine than they were when vaccine research began, BBC News reports (Briggs, BBC News, 2/15).
- Data presented at the American Society of Clinical Oncology meeting suggest that 15% of patients who took sunitinib (Sutent®) developed heart failure. Researchers studied 48 patients with kidney cancer or gastrointestinal stromal tumor (GIST) on sunitinib and noted that 7 (15%) experienced heart failure. The problems began between 22 days and 435 days after beginning therapy, although most started within the first three months of treatment. Individuals with a history of heart failure, coronary artery disease or low BMI were at an even higher risk and 3 of 5 patients followed long term continued to have heart problems even after the drug was stopped. The researchers call for routine cardiac monitoring in patients receiving sunitinib and for cardiac adverse effects to be carefully examined in future trials of the drug. Previously, a retrospective analysis of phase I/II data published in the Lancet had noted the development of cardiovascular adverse events, including heart failure, in some patients with GIST who took the drug (see NeLM link). At the time of the Lancet paper, Pfizer released a statement agreeing that these cardiac risks do exist but added that they "were medically manageable in most patients and underscore the importance of having a collaborative team of health-care professionals working together to appropriately manage patients who have limited available options" in treating their cancer.